|Last Price$35.40||Day Change (%)0.06%|
|Open Price$35.25||Day Change ($)0.02|
|Day Range35.16–35.40||52-Week Range29.56–36.66|
As of Sat 2/17/2017 8:59:00 PM | USD
Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma
Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
While more than one third of these top fund managers are outperforming this year, four of them stand out from the rest given their ability to outperform the market over almost all time periods.
Pepco deal, power prices, capacity markets, carbon caps: It’s been a wild ride for Exelon in 2014.